Johnson & Johnson has appointed Thibaut Mongon as Chief Executive Officer Designate and Paul Ruh as Chief Financial Officer Designate of its consumer health division, which is due to be split from its medical device and pharmaceutical units next year.
The company announced the planned separation last year to create two separate businesses – the new Johnson & Johnson and the New Consumer Health Company. J&J claims the move will ensure both companies are “better positioned to deliver improved health outcomes for patients and consumers through innovation, pursue more targeted business strategies and accelerate growth.”
This leadership transition will occur upon completion of the planned separation of the Consumer Health business, expected to occur during 2023. Further director and leadership appointments are expected to be announced in the coming months as the separation process progresses.
Mongon has worked for J&J for more than 20 years and is currently Executive VP and Worldwide Chairman of its Consumer Health division. Ruh joined J&J five years ago from PepsiCo to become the CFO of the Consumer Health business.
Joaquin Duato, the current group CEO, commented: “With Thibaut at the helm, we can expect the New Consumer Health Company to remain mission-driven with iconic, science-backed brands and a strong commitment to innovation and remarkable talent. He will be supported by Paul, who brings a strong track record of delivering transformational improvements and who has in-depth knowledge and expertise of the consumer goods industry. I am confident that Thibaut and Paul are the right leaders to deliver significant value for stakeholders.”
